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Biology-based markers to conﬁrm or aid in the diagnosis or prognosis of chronic graft-versus-host disease
(GVHD) after allogeneic hematopoietic cell transplantation or monitor its progression are critically needed to
facilitate evaluation of new therapies. Biomarkers have been deﬁned as any characteristic that is objectively
measured and evaluated as an indicator of a normal biological or pathogenic process, or of a pharmacologic
response to a therapeutic intervention. Applications of biomarkers in chronic GVHD clinical trials or patient
management include the following: (1) diagnosis and assessment of chronic GVHD disease activity, including
distinguishing irreversible damage from continued disease activity; (2) prognostic risk to develop chronic
GVHD; and (3) prediction of response to therapy. Sample collection for chronic GVHD biomarkers studies
should be well documented following established quality control guidelines for sample acquisition, processing,
preservation, and testing, at intervals that are both calendar and event driven. The consistent therapeutic
treatment of subjects and standardized documentation needed to support biomarker studies are most likely to
be provided in prospective clinical trials. To date, no chronic GVHD biomarkers have been qualiﬁed for use in
clinical applications. Since our previous chronic GVHD Biomarkers Working Group report in 2005, an increasing
number of chronic GVHD candidate biomarkers are available for further investigation. This paper provides a 4-
part framework for biomarker investigations: identiﬁcation, veriﬁcation, qualiﬁcation, and application with
terminology based on Food and Drug Administration and European Medicines Agency guidelines.
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ty for Blood and Marrow Transplantation.BACKGROUND
Chronic graft-versus-host disease (GVHD) is 1 of the most
important long-term complications of allogeneic blood and
marrow transplantation, resulting in signiﬁcant morbidity
and mortality [1]. Unlike acute GVHD, chronic GVHD is
insidious in its onset and the diagnosis can be difﬁcult.
S. Paczesny et al. / Biol Blood Marrow Transplant 21 (2015) 780e792 781Moreover, chronic GVHD is a multifaceted disease that can
affect almost all organs and tissues in the body. Thus, the
identiﬁcation and veriﬁcation of biomarkers for chronic
GVHD is more difﬁcult than for acute GVHD. The scoring
system proposed by the National Institutes of Health (NIH)
Consensus Development Project on Criteria for Clinical Trials
in chronic GVHD [2] has now been widely adopted by he-
matopoietic cell transplantation (HCT) centers. However,
clinical characteristics are not fully informative in predicting
the severity of the disease, response to therapy, or survival,
and they are not adequate to distinguish disease activity
from irreversible tissue damage during treatment [3]. As an
adjunct to clinical and histological criteria, the availability of
biomarkers for chronic GVHD could potentially improve the
classiﬁcation of patients into risk groups and thereby reﬁne
chronic GVHD diagnosis, estimate the risk of developing
chronic GVHD, or predict response to therapy.
The pathogenesis of chronic GVHD involves a number of
biological mechanisms potentially contributing to its devel-
opment and evolution. Historically, chronic GVHD was
believed to be a chronic continuation of the same effector
mechanisms that cause acute GVHD, ie, donor T cells having
speciﬁcity for recipient-restricted histocompatibility anti-
gens that produce cytokines. However, differences in the
clinical presentations of acute and chronic GVHD suggest
that the effector mechanisms might differ. Further, therapies
that are clinically effective in treating acute GVHD are much
less effective for chronic GVHD. Together, this suggests that
both unique biomarkers and pathophysiologic mechanisms
may be involved in chronic GVHD.
Candidate biomarkers may be identiﬁed from their cor-
relations with certain chronic GVHD phenotypes. Although
some correlations might not reﬂect the underlying pathol-
ogy, others will suggest new pathophysiologic pathways and
potential therapeutic targets. Alternatively, potential bio-
markers may be identiﬁed via biological hypotheses gener-
ated from preclinical or theoretical models of chronic GVHD
pathophysiology. However, a biomarker does not necessarily
directly represent an effector mechanism of chronic GVHD
but may reﬂect a counter-response to control GVHD or result
from nonspeciﬁc inﬂammation or damage.Purpose of This Document
The purpose of this document is to facilitate the identi-
ﬁcation, veriﬁcation, qualiﬁcation, and application of chronic
GVHD biomarkers. In this document we discuss the
following: (1) a standardized nomenclature for biomarkers
usage, (2) a core set of potentially confounding factors that
must be considered when measuring different types of
chronic GVHD biomarkers, (3) critical concepts and a rec-
ommended decision process speciﬁc to the selection and
development of biomarkers in chronic GVHD, and (4) con-
siderations for a repository with the minimal essential clin-
ical data to be provided with each sample.Summary of 2014 Changes
This document replaces the 2005 report [4] of the
Biomarker Working Group of the NIH Consensus Develop-
ment Project on Criteria for Clinical Trials in chronic GVHD.SUMMARY OF RECOMMENDATIONS
The Biomarker Working Group makes the following
recommendations:1. Biomarker(s) of chronic GVHD should include all of the
following components whenever possible:
a. Marker should be identiﬁed as diagnostic, prog-
nostic, or predictive of the potential to respond to a
treatment, or it should correlate with response to a
treatment that will lead to an important clinical
outcome (see Table 1).
b. Use of rigorous methodology for measuring the
biomarker.
c. Conﬁrmation in at least 2 independent cohorts, each
having sufﬁcient power for statistical signiﬁcance
for a clinically relevant hypothesis.
This rigor is required because the observation of a sig-
niﬁcant association in a single data set does not ensure that
the ﬁndings can be generalized to other data sets or that the
association is speciﬁc for the investigated condition. A
biomarker conﬁrmed to have a strong association with the
investigated condition in at least 2 independent cohorts
would support its use in chronic GVHD clinical trials or pa-
tient management. To identify such biomarkers, a coordi-
nated approach to the identiﬁcation, veriﬁcation,
qualiﬁcation, and application of biomarkers should be
implemented. Before clinical application, a higher degree of
conﬁdence may be required, such as conﬁrmation of results
by an independent group in a different environment and
clinical setting.
2. Both hypothesis-driven studies and discovery-based
approaches for identiﬁcation of chronic GVHD bio-
markers are likely to be successful in different
circumstances.
3. Ideally, both chronic GVHD observational prospective
studies and chronic GVHD clinical therapeutic trials
should include correlative biological studies to allow
the identiﬁcation, veriﬁcation, qualiﬁcation, and
application of biomarkers whenever possible. The
main advantages of observational prospective studies
are the following: (1) the study population can be
more heterogeneous and representative of the entire
population, (2) they have generally longer longitudinal
follow-up than clinical trials, and (3) more patients can
be studied. Clinical trials have the advantages that the
following advantages: (1) the study population is often
more homogeneous, (2) treatment is controlled, (3)
clear outcome assessment, and (4) if randomized, po-
tential sources of bias are minimized.
4. Samples from well-documented cases and controls
should be stored using standardized protocols as pro-
posed in this consensus paper, to create a resource for
future biomarker studies. Samples types to be
collected on cases and controls and minimal essential
clinical data to be provided with each sample are
detailed below.DEFINITIONS OF BIOMARKERS AND THEIR
APPLICATIONS
A biomarker has been deﬁned by the NIH Biomarker
Working Group as a characteristic that is objectively
measured as an indicator of normal biological or pathogenic
processes, or biological and clinical responses to a thera-
peutic intervention [5]. The Institute of Medicine has further
deﬁned objectively to mean “reliably and accurately” [6]. The
term biomarker commonly refers to a biochemical variable
Table 1
Revised Deﬁnitions of Biomarkers Biomarkers*
Types of Biomarkers Recommended Change in Deﬁnition Uses Minimum Matching Criteria
for Control Samplesy
Modiﬁed from Biomarker
Deﬁnition in Previous
NIH Chronic GVHD
Consensus Criteria (2006)
Diagnostic An assay that identiﬁes patients at the onset of clinical disease
- Different forms of chronic GVHD may have different markers
- Different tissues may have different markers
To help in rapid diagnosis
and initiation of therapy
 Time from transplantation
 Absence of relapse
 Absence or presence of current
or recent acute GVHD
 Absence or presence of active infection
 Absence of recent B cell depletion
after BMT
 Manipulation or treatment of the donor
product (ie, TCD, G-CSF)
“Diagnose chronic GVHD.”
Prognostic An assay that categorizes patients by degree of
risk for disease occurrence or progression or resolution
A prognostic biomarker provides
information about the anticipated course of
the disorder in that particular patient
 Time from transplantationz
 Prior acute GVHD
 T or B cell depletion during conditioning
“Predict risk of
developing
chronic GVHD.”
Predictive An assay that categorizes patients by their likelihood of
response or outcome to a particular treatment when
measured before the treatment
A predictive biomarker provides
information about whether a given patient is
likely to respond to a treatment intervention
in a particular way
 Time from transplantation
 Current immune suppressive therapy
(eg, glucocorticosteroids,
calcineurin inhibitors)
 NIH global severity score
“Predict response
to therapy.”
“Assess prognosis or
establish staging of
chronic GVHD.”
Response to treatment An assay measured after initiation of therapy
that is intended to substitute for a clinical efﬁcacy endpoint
(note: a pretherapy sample for comparison is required)
A response marker that can be utilized in place of
an accepted clinical response endpoint (see the
NIH chronic GVHD response criteria paper)
 Time from transplantation
 Absence of relapse
 Absence or presence of current
or recent acute GVHD
 Absence or presence of active infection
 Absence of recent B cell depletion
after BMT
 Manipulation or treatment of the donor
product (ie, TCD, G-CSF)
“Measure disease activity.”
Prior biomarker deﬁnition
that was removed in
revised NIH criteria
“Evaluate GVHD versus
graft-versus-leukemia or
graft-versus-tumor effect.”
BMT indicates bone marrow transplantation; TCD, T cell depletion; G-CSF, granulocyte colonyestimulating factor.
* The Predictive and prognostic deﬁnitions have been modiﬁed to be consistent with current FDA and EMA guidelines [7,8].
y For cGVHD diagnosis in the ﬁrst 2 years controls that do not have cGVHD should be obtained within 2 months of the index case and for patients diagnosed with cGVHD after 2 years post- transplantation controls should be
match to within 1 year from diagnosis.
z First 2 years: within 2 months, After 2 years: within 1 year. Appropriate time interval could be different in adult versus pediatric patients due to a faster immune reconstitution in pediatric patients.
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purposes of this document, certain evaluations that are
routinely performed to determine the diagnosis of chronic
GVHD or to assess the clinical severity of the disease are not
discussed but may be considered as biomarkers in certain
circumstances. Examples of such evaluations include pul-
monary function testing, liver function testing, and radio-
graphic assessment, including computed tomography scans.
Biomarkers can be separated into distinct categories of
diagnostic, prognostic, and predictive (including response
biomarkers), as described in Table 1. Applications of chronic
GVHD biomarkers critical to clinical care and research
studies are summarized below and in Table 1. The deﬁnitions
have been updated to reﬂect usage by the Food and Drug
Administration and European Medicines Agency [7,8].
1. Diagnose chronic GVHD. For example, a biomarker
could be used together with clinical criteria to deter-
mine eligibility for a clinical trial or clarify differential
diagnosis (eg, infection, drug reaction, other inﬂam-
matory disease versus chronic GVHD). Distinguish cu-
mulative damage or irreversible tissue damage from
current chronic GVHD activity. Many of the organ sys-
tems involved in chronic GVHD develop cumulative
tissue damage, and grading scales do not distinguish
well between the extent of current areas of inﬂam-
matory activity (eg, inﬁltrates of lymphocytes into
tissue) and cumulative damage (sclerotic scarring, loss
of lacrimal or salivary function due to loss of secretory
acini). Identify candidates for pre-emptive therapy. For
example, anti-HY titers increase weeks to months
before clinical manifestations and may identify can-
didates for pre-emptive therapy or suggest the type of
treatment that should be used.
2. Prognostic risk to develop chronic GVHD. For example,
gene polymorphisms in either the donor or recipient
may be associated with risk of development of
chronic GVHD. Identifying prognostic markers for
development of severe forms of chronic GVHD,
before onset or at the time of initial diagnosis
chronic GVHD, is of particular interest. For example,
a biomarker that could estimate the risk of severe
GVHD leading to serious sequelae would be useful to
help guide decisions about the need for and in-
tensity of treatment.
3. Predict potential for response to therapy. For example, a
biomarker may distinguish between different patho-
physiologic processes that cause chronic GVHD and aid
in determining treatments that are most likely to
provide beneﬁt for an individual patient.
4. Serve as an intermediate marker of response to treat-
ment, particularly a response related to a long-term
outcome, such as nonrelapse mortality. For example, a
biomarker could be used to monitor therapeutic
response. This type of biomarker could also help guide
decisions about treatment management by revealing
that a treatment has not resulted in an adequate
response and that a change in treatment is warranted.
Biomarkers that could be used to predict response to
treatment, measure disease activity or distinguish reversible
disease activity from irreversible damage would have very
high clinical utility, as currently available clinical tools are
not adequate for these purposes. In addition, biomarkers that
are prognostic for the risk of developing severe chronicGVHD would also have high utility and could be used in pre-
emptive trials.
Predictive biomarker studies will have to be annotated
not only with demographic and GVHD-related data available
at the time of collection, but also with GVHD data relevant to
future outcomes. Ideally, samples stored in biorepositories
will have outcome data as well, butmany times are not set up
this way. The Center for International Blood and Marrow
Transplant Research transplant essential data forms have a
lower level of detail regarding chronic GVHD than may be
required for some predictive biomarker evaluations. If
possible, samples should be deidentiﬁed to the repository,
and the donating center should retain the identiﬁcation
links. When biomarker studies are performed, investigators
could then contact the centers that donated the sample to
update the data.
RISK FACTORS AND COVARIATES TO CONSIDER
Although a biomarker may provide valuable assessment
of chronic GVHD, other contributing and confounding con-
ditions must also be considered. Some potential confounding
factors are deﬁned below and summarized in Table 2.
Factors Affecting Biomarkers Directly and Independent of
Onset of Chronic GVHD
The conditions of (1) immune reconstitution, (2)
concomitant acute GVHD, (3) the type and intensity of cur-
rent immunosuppressive therapy, (4) presence of infections,
and (5) sample processing and storage may all affect
expression of a chronic GVHD biomarker or its measurement
and interpretation. In particular, the analysis of immune-
related biomarker data must also account for time from
transplantation, as immune reconstitution occurs gradually.
Organ involvement by chronic GVHD (types of tissues
involved and NIH score) and the clinical presentation at
onset reﬂect the chronic GVHD diagnostic phenotype, which
may directly affect biomarker levels. Because of the hetero-
geneity and varied frequency of the clinical syndromes of
chronic GVHD, it is unlikely that any given biomarkers will be
applicable to all forms or presentations of this disorder.
Covariates and Potential Confounding Factors
A variety of confounding factors may limit the ability to
interpret results of chronic GVHD biomarker studies. Each of
the following confounding factors may limit the scope and
application of a particular biomarker or at least must be
controlled for as possible confounding factors in any anal-
ysis: (1) recipient characteristics, such as age; (2) donor
characteristics, including treatment of the donor with gran-
ulocyte colonyestimulating factor or other agent (eg, pler-
ixafor) and graft manipulation (eg, an HLA-haploidentical
graft with T cell depletion or with administration of cyclo-
phosphamide after transplantation); (3) donor source
(related versus unrelated) and the type of graft (peripheral
blood, bone marrow, or umbilical cord blood); and (4)
recipient preparative conditioning regimen.
Donor versus Recipient Chimerism Criteria for
Evaluation of Chronic GVHD Biomarkers
Signiﬁcant recipient chimerism is associated with a
higher frequency of donor tolerance [9,10] and could affect
the interpretation of chronic GVHD biomarkers when donor-
derived hematopoiesis is not fully engrafted. In patients with
questionable engraftment, chimerism should be examined,
and the patient should be excluded from biomarker studies if
Table 2
Factors that Must be Considered for Chronic GVHD Studies
Factor Impact on Chronic GVHD Biomarker
Factors affecting biomarkers directly
Tissues involved and NIH chronic GVHD score  Tissues involved
 NIH chronic GVHD score
Immune reconstitution after HCT
and time from transplantation
 Some biomarkers vary with immune reconstitution after HCT; thus, time and age-matched
(pediatric versus adult) controls are required.
Concomitant acute GVHD  Concurrent acute GVHD may overlap with classic chronic GVHD manifestations
 Biomarkers may represent late acute GVHD manifestations
Previous acute GVHD and treatment/
prophylaxis of acute GVHD
 The presence of previous acute GVHD and the therapy utilized to treat acute GVHD
 Acute GVHD prophylaxis has the potential for long term impact on immune reconstitution
(eg, antibodies such as rituximab, alemtuzumab, and ATG)
Current immune suppression  Many immunosuppressive treatments particularly steroids may affect concentrations affect
concentration of biomarkers (eg, sBAFF)
Current infection  Active infections may change cytokine milieu and markers.
 CMV reactivation, pulmonary infections.
Sample processing and storage  Some B cell populations are lost when processed with Ficoll
 Choice of serum or heparin, EDTA, or citrate plasma alters analytes
 Processing time after blood draw reduces some analytes
 Collection of the samples may be speciﬁc for the type of assay and the type of tissue collected
(ie, serum, urine, saliva)
These considerations apply both during the identiﬁcation and veriﬁcation of a biomarker as well
as during its subsequent application.
Covariates and potential confounding factors
Recipient characteristics  Younger age associated with lower incidence of chronic GVHD
 Nonmalignant diagnoses may affect the incidence and type of chronic GVHD (particularly
nonmalignant disorders with marrow failure and chromosomal instability appear to have a
higher rate of chronic GVHD).
 Allo-immunized patients may have a lower rate of engraftment resulting in split
donor chimerism and affecting the incidence of chronic GVHD
 Non-HLA polymorphisms may impact incidence or presentation (ie, ABO incompatibility)
 Biomarkers may be organ speciﬁc
Donor characteristics  Unrelated versus related donor
 HLA mismatched versus HLA matched
 Female donor is associated with a higher incidence of chronic GVHD
 UCB, peripheral blood, or marrow graft
 Non-HLA polymorphisms may impact on incidence or presentation (ie, ABO incompatibility)
 Treatment of donor product (ie, G-CSF, T cell or B cell depletion)
Preparative conditioning regimen  MAC versus RIC
 Use of T cell or B cell depletion (ATG, alemtuzumab, rituximab), all associated with a lower
incidence of chronic GVHD
 TBI associated with increased cutaneous sclerosis
ATG indicates antithymocyte globulin; BAFF, B celleactivating factor; CMV, cytomegalovirus; UCB, umbilical cord blood; MAC, myeloablative conditioning; RIC,
reduced-intensity conditioning; TBI, total body irradiation.
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lymphoid or myeloid populations.
CRITICAL FRAMEWORK FOR BIOMARKER STUDIES IN
CHRONIC GVHD
So far, most potential chronic GVHD biomarkers have
been identiﬁed based on evaluation at a single center or
single laboratory and have not been through all the steps of
veriﬁcation and qualiﬁcation necessary to be approved for
use in clinical trials, as discussed below and shown in
Figure 1. Only a few studies have included patients derived
from multiple centers or independent cohorts of patients.
Thus, we propose a 4-part framework for the development of
chronic GVHD biomarkers (Figure 1). These recommenda-
tions are based on guidance for biomarker development
from the Institute of Medicine [6] and the US Food and Drug
Administration in the Center for Drug Evaluation and
Research [11]. The HCT community will be able to move
forward and translate biomarkers into the clinic only if these
recommendations are carefully applied to avoid previous
mistakes, such as (1) strong reliance on convenience samples
rather than a prospectively deﬁned population from which
specimens are to be collected; (2) absence of a veriﬁcation
cohort that is independent of the discovery cohort; (3)
improper statistical methods, for example, when deriving amultiple factor risk score; and (4) failure to consider
commonly available clinical information before deducing the
additive value of biomarkers. Avoidance of these mistakes
will allow our HCT community to move forward in trans-
lating biomarkers into the clinic [12,13]. We have used the
new recommended terminology in the headers below [5,6]
to avoid the term validation, whose different meanings
have led to confusion. In Figure 1 we propose a workﬂow for
biomarker discovery. Each step is explained below.Step 1: Identiﬁcation
The initial step is the identiﬁcation of candidate bio-
markers in a small experiment of well-matched cases and
controls selected from the populations in which the
biomarker is intended for use. At this initial step, it is
important to deﬁne the clinical context of use and the
clinician-reported outcome or patient-reported outcome
data that will be captured to assess a clinical endpoint, for
example, nonrelapse mortality, relapse mortality, or more
chronic GVHD-speciﬁc scales, such as the NIH chronic GVHD
0 to 3 organ score and the Lee chronic GVHD symptom scale.
The most appropriate controls for the cases should be
deﬁned at this point. It should not be assumed that the same
controls are appropriate for different clinical contexts.
Table 3
Statistical Considerations
A. Analytical performance parameters
 Precision (repeatability and reproducibility of an assay)
 Accuracy
 Assay sensitivity (limit of detection)
 Assay speciﬁcity (interference, cross-reactivity)
 Sample type and matrix
 Sample preparation
B. Diagnostic accuracy
 Sensitivity: Proportion of subjects in a sample of patients with the
target condition in whom the test is positive.
 Speciﬁcity: Proportion of subjects in a sample of patients without
the target condition in whom the test is negative.
 Receiver operator characteristic: A plot of the true-positive rate
versus the false-positive rate for all possible thresholds of a
biomarker.
 Positive predictive value: Proportion of patients in the overall
population with a positive test who have the target condition.
 Negative predictive value: Proportion of patients in the overall
population with a negative test who do not have the target
condition.
Figure 1. Example of a predictive biomarker or response biomarker devel-
opment project.
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are discussed in Table 2.Step 2: Veriﬁcation
This step conﬁrms the analytical validity of a test. This
includes, among other aspects, the test’s reproducibility and
accuracy (percent coefﬁcient of variation, precision). Test
practicality should also be considered: Is the potential sam-
ple to be measured easy to obtain, is the sample stable until
the test can be performed, and is it cost-effective? Of note,
before the qualiﬁcation step, parameters such as cutoff
values and sample collection procedures are locked down
(ﬁnalized) and cannot be changed without reveriﬁcation of
the test under the revised conditions.Step 3: Qualiﬁcation
This step assesses the robustness of the test in all samples
from the intended use population for a certain clinical
outcome/clinician-reported outcome or patient-reported
outcome (ie, correctness). Statistical considerations for this
step are shown in Table 3. Other statistical analyses that have
been proposed to estimate the performance of biomarkers
are reviewed by Pepe et al. [14]. The qualiﬁcation cohort for
step 3 should be entirely distinct and separate from the
identiﬁcation cohort previously studied in step 1, including
different center(s) and different demographics, so long as
they are consistent with the intended use population. If,
however, the demographics are too different from the pop-
ulation for which the biomarker’s use is intended, qualiﬁ-
cation testing could fail inappropriately.Step 4: Application
In this ﬁnal step, the biomarker is used in the clinic
(eg, to test all patients suspected of having chronic GVHD)
or in a prospective randomized clinical trial, to test the
potential to foretell the outcome. If the biomarker suc-
cessfully qualiﬁed, the application step may test the
following: (1) practicality of use in a consortium study, (2)
replacement of a clinical scoring system or invasive bi-
opsies by a simple blood test, or (3) usefulness as an early
surrogate indicator of response when testing a new drug
as compared with the standard of care. Application testing
may require institutional review board approval as well as
investigational device exemption or investigational new
drug approval, if clinical management of patients in the
study is based on the outcome of the test.ENSURING ADEQUATE PATIENT CONSENT FOR CHRONIC
GVHD BIOMARKER STUDIES
To allow chronic GVHD biomarkers studies, obtaining
consent at the time of sample collection is essential.
Obtaining consent for both current and future research
studies can be accomplished most easily by the appropriate
provision at the time of enrollment, in advance of any sample
collection followed by deidentifying the sample and
providing the correlative clinical data. To obtain consent that
allows for a broad variety of clinical studies and sharing with
other investigators, a graded level of consent may need to be
obtained in the initial consenting process, clarifying whether
the participant will allow (1) studies on the sample as per the
currently outlined studies, (2) storage for future studies in
chronic GVHD, and (3) storage for future studies that may
involve disorders other than chronic GVHD. Because of so-
cietal sensitivities around “genetic testing” and the common
requirement for deposition of genetic information into
public databases, specialized consent should be obtained for
gene-based studies. The consent process should strive to
allow for testing or research exchange of coded samples, a
process that protects the identity of the subjects but allows
access to necessary clinical data through the original
provider.
Table 4
Minimal Essential Clinical/Routine Laboratory Data to Be Provided with Each Sample
Essential Data Recommended Data (will be Marker Speciﬁc)*
1. Clinical Phenotype
For diagnosis markers: NIH diagnosis and staging forms
For prediction of response: NIH response to treatment forms
This includes presence or not of concomitant features of acute GVHD
Time after transplantation at chronic GVHD diagnosis or of time matched
non-chronic GVHD patients
2. Current type of immunosuppression at the time of time of sample
collection (if taking corticosteroids, add dose and weight of patient)
1. Prior acute GVHD
2. MAC versus RIC
3. Prior chronic GVHD
4. TCD versus not TCD
5. PBSC versus BM versus UCB
6. Recent B cell depletion
7. Sex mismatch
8. HLA mismatch
9. Active uncontrolled infection (particularly CMV)
10. Age of the patient and recipient
11. WBC and ALC (although suggested they are not routinely
captured at most centers)
12. Prior immunosuppressive therapies failed
13. Absolute T and B cells counts
14. IgG levels
PBSC indicates peripheral blood stem cells; BM, bone marrow; ALC, absolute leukocyte count.
* Variables that could confound the analyses (Table 2) should be collected in minimal essential data.
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The largest barrier to new chronic GVHD biomarker
development is the lack of good quality biological samples
linked to detailed clinical data. Well-conducted, large,
multicenter, observational or interventional clinical trials
represent excellent formats to provide the consistency of
standardized documentation needed to support qualiﬁcation
studies correlating biomarkers with clinical endpoints of
interest. However, single-institution or observational studies
with limited institutional participation in which standard-
ized diagnostic criteria are employed may be sufﬁcient for
initial identiﬁcation studies.
These sample repositories not only would support the
exchange of chronic GVHD patient materials for veriﬁcation
of currently proposed biomarkers, but also provide a
resource for biomarker discovery through implementation of
new technologies. Multiple new technologies are becoming
available for analysis of biological ﬂuids, including serum,
plasma, saliva, bronchoalveolar lavage ﬂuid, and urine. The
proteome and metabolome [15,16] can be analyzed by
multiplex ELISA [17], and peptide arrays can be used to
identify autoantibody epitopes [18]. Preserving leukocytes
supports future characterization of populations with ﬂow
cytometric analyses using as many as 20 ﬂuorochrome
channels or 40 channels with mass cytometry [19]. Preser-
ving cells also supports cell typeespeciﬁc sorting for mo-
lecular analyses. Multiparameter cell characterization can
also be done with parafﬁn-embedded pathology specimens
by ﬂuorescent immunohistochemistry with imaging through
confocal microscopes and multispectral ﬂuorescent imaging
analysis supported by quantitative analysis software [20].
RNA and DNA can be recovered from preserved leukocytes,
snap-frozen tissue biopsies, from parafﬁn sections, or even
from speciﬁc tissue areas in sections through laser capture
microdissection [21]. Analyses of RNA and miRNA tran-
scriptomes have been used to characterize gene expression
patterns in autoimmunity and inﬂammation [22,23]. New
bead arrays permit mapping of epigenetic DNA hypo-
methylation to speciﬁc gene loci [24]. Veriﬁcation of identi-
ﬁed genes individually by quantitative RT-PCR is being
replaced by platforms utilizing direct multiplexed measure-
ment with RNA and miRNA probe sets, incorporating
hundreds of genes to identify multigene patterns [25]. High-
throughput exome sequencing can identify relevant gene
polymorphisms in donors and recipients more rapidly and atlower cost than whole genome approaches, and RNAseq can
identify both expression and altered sequences in expressed
transcripts in sorted, well-deﬁned cell subsets. Key to the
integration of data from these methodologies is the rapidly
maturing development of powerful tools for analysis and
interpretation of results.
When future biomarker studies are designed, we propose
the following considerations. The proposed collection and
banking of specimens and data can be very expensive and
will require support from research funding sources.
1. Prospective multicenter studies with collection and
banking of sampleswith an accompanying patient data
link, in a manner that complies with regulations for
disclosure of protected health information of the
country in which the trial is being performed. Asses-
sors will require adequate training to collect the clin-
ical data correctly. The chronic GVHD-focused clinical
variables of interest are outlined in the companion NIH
Consensus Development Project on Criteria for Clinical
Trials in Chronic GVHDWorking Group reports. Table 4
presents the minimal recommended data elements
that should be linked with each stored sample.
2. Sample acquisition protocols should incorporate both
calendar-driven time points and event-driven sample
collection. Examples of event-driven sample collection
include the point when the patient is ﬁrst diagnosed
with chronic GVHD (or within 2 months) or before
start of systemic treatment or at the time of change
in treatment. Thus, in the presence of chronic GVHD,
we recommend that samples should be obtained
within 2months of onset or treatment change. Because
the immune environment changes with post-
transplantation immune reconstitution, time-
matched samples should also be obtained from
patients who do not have chronic GVHD to serve as
controls. In the absence of chronic GVHD, we recom-
mend that samples should be obtained at 3, 6, and 12
months, with additional sampling considered at 9
months, and 18 to 24 months after transplantation.
Ideally, additional samples should be collected yearly,
if possible for 6 to 8 years, especially if studies on long-
term changes associated with established chronic
GVHD are being considered. This schedule will
adequately provide samples during the period of
greatest risk for development of chronic GVHD and
Table 5
Candidate Chronic GVHD Biomarkers*
Category Diagnostic Prognostic/Risk Stratiﬁcation Predictive
Cellular Mediator Antibodies Cellular Mediator Gene
polymorphism
Cellular Mediator Antibodies
Evidence-based
Category 1
B cells [39-44]
Treg [45-47]
BAFF [17]
CXCL9 [17]
elaﬁn [17]
Aminopeptidase N
(sCD13) [17]
sIL-2Ra [17]
IL-4 [48,49]
IL-6 [50,51]
TNFa [50,51]
Treg [45-47,52,53] TNFa [52-54] IL-10 [55-59]
IL-6 [60-62]
TNFa [56,63,64]
Treg [65-68]y sIL-2Ra [69,70]
Evidence-based
Category 2
BAFF/B cell [43]
CD3þ T cells [39]
Effector memory (CD4þ
and CD8þ)
[71,72]
Monocytes [73]
Naïve CD8þ T cells [71]
NK cells [39]
Th17 cells [50]
TLR-9 responsive B cells [44]
ADAMTS2 [74]
ADAMTS3 [74]
AREG [74]
BCAT1 [74]
CPM [74]
CXCL10 [75]
CXCR3 [75]
CXCR7 [74]
DAP2IP [74]
haptoglobin [76]
IFN-g [48]
IL-1b [51]
IL-1Ra [77]
IL-1R2 [74]
IL-2 [48]
IL-8 [50]
IL-10 [77]
IL-12 [49]
IRS2 [74]
SRGAP1 [74]
lactotransferin/lactoperoxidase
(salivary) [78]
IL-1Ra þ CTSB (salivary) [79]
ANA [80]
Anti-dsDNA [69]
Anti-PDGFR [81]
H-Y antibodies [82]
B cells [43]
DC2 [83]
NK [84,85]
BAFF [86]
BAFF/B-cell ratio
[86]
b-FGF [87]
IFN-g [53]
IL-10 [53]
IL-15 [88]
TGFb [52]
VEGF [87]
BAFF [89]
CCR6 [90]
CCR9 [91]
FAS [56]
FCRL3 [92]
Haptoglobin [76]
Heparanase [93]
HMGB1 [94]
IFN-g [95]
IL-1 [61]
IL-1Ra [57]
MadCAM-1 [96]
MICA [97]
PARP1 [98]
Immature/memory
B cell ratio [41]
Th17 cells [50]
TLR-9 responsive
B cells [44]
BAFF [69] Anti-PDGFR
[99]
Treg indicates regulatory T cells; CXCL, chemokine (C-X-C motif) ligand; NK, natural killer; TLR-9, toll like receptor 9; ATAMTS, A Disintegrin And Metalloproteinase with Thrombospondin Motifs; AREG, amphiregulin; DAP2IP,
disabled homolog 2, mitogen-responsive phosphoprotein; IRS2, insulin receptor substrate 2; SRGAP1, SLIT-ROBO rho GTPase-activating protein 1; PDGFR, platelet-derived growth factor receptor; BAFF, B cell-activating factor;
DC2, dedritic cells type 2; b-FGF, basic ﬁbroblast growth factor; VEGF, vascular endothelial growth factor; CCR, C-C chemokine receptor; FAS, Fas cell surface death receptor; FCRL3, Fc receptor-like protein 3; HMGB1, High-
mobility group protein B1; MadCAM-1, mucosal vascular addressin cell adhesion molecule 1; MICA, MHC class I polypeptide-related sequence A; PARP1, Poly [ADP-ribose] polymerase 1.
The table presents a synthesis of published candidates chronic GVHD biomarkers organized according to application. Importantly, these are candidates based on current knowledge. Additional replication of these ﬁndings is
needed, and none of the summarized candidates meet criteria for qualiﬁcation. The table presents general biomarker candidates and does not speciﬁcally present data on association between biomarker candidates and chronic
GVHD organ involvement or severity.
Deﬁnitions: Diagnostic, distinguish chronic GVHD from non-GVHD controls; risk stratiﬁcation, determine risk for chronic GVHD development; predictive, assess therapeutic response; cellular, immune cell populations;
mediator, inﬂammatory or immune regulatory cytokines and other factors; antibodies, auto-antibodies detected in chronic GVHD; gene polymorphism, reported cytokine gene polymorphism associated with chronic GVHD;
category 1, biomarkers supported by greater quality evidence, including consistent ﬁndings (eg, candidate biomarker is elevated in chronic GVHD patients versus controls) across  2 studies, regardless of methodology used in
each report, or examined in 2 patient cohorts; category 2: studies have demonstrated signiﬁcant ﬁndings in a single cohort, or by a single group.
* Some of the markers have been evaluated in more than 1 independent patient cohort by either the original groups to identify the marker or by another laboratory. Moreover some markers have been identiﬁed by different
methodologies when separate laboratories have evaluated the marker. We have not noted these differences in this table.
y This marker could be considered in the category response to therapy.
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treatment.
3. A centralized repository at the National Marrow Donor
Program or possibly a virtual repository with multiple
sites collecting in a standardized manner should be
established. In the Blood and Marrow Transplant
Clinical Trials Network 1201 trial on acute GVHD,
shipping of blood up to day þ100 has provided mate-
rials for processing in a central site. Collection directly
into EDTA, Cyto-chex, and PAXgene tubes has provided
material for studies of plasma antibodies and stable
cytokines, ﬂow cytometric phenotyping of lympho-
cytes and preservation of RNA for molecular analyses.
This powerful approach avoids the need to have
specialized local facilities for processing and preser-
vation and standardizes processing and assays to
ensure consistent results [26-28]. However, this
approach is limited in 3 ways. First, plasma cytokines
and chemokines are sensitive to both the choice of
anticoagulant and the time interval from collection to
processing and storage [27,29]. At individual sites with
dedicated core facilities, rapid separation and freezing
of serum and plasma (both heparin and EDTA) are
recommended for better preservation of cytokines and
chemokines. Storing multiple small aliquots (.5 to 1
mL/vial for plasma/serum, 2  106 for phenotyping
studies, and 5  106 cells for functional studies per vial
with ideally 5 vials for each patient and time point)
avoids refreezing. The volume of blood or tissue
collected must be compliant with institutional review
board maximum criteria. Unusual methods to obtain
cells, such as leukapheresis, must be considered care-
fully regarding the risks to the subject. Collection in
multiple anticoagulants is preferred, as the anticoag-
ulant choice affects measured ELISA cytokine levels
and may limit metabolome recovery [27,30-32]. Sec-
ond, storing blood cells for later analysisdparticularly
in numbers adequate for ﬂow cytometry (at least 5 
106 cells) has the advantage of preserving valuable
patient materials for ﬂow cytometric, molecular, and
functional assays using rapidly developing new tech-
nologies. Finally, the calendar-driven sample approach
is inﬂexible in timing and limited in scope of tissues
examined. Collection of event-driven samples, such as
on the day of diagnosis or of new organ involvement,
may be critical to identifying transient biomarkers.
Chronic GVHD is pleomorphic; biopsies of chronic
GVHD target organs (skin, intestine, liver, and mucosa)
or collection of local bioﬂuids such as saliva or bron-
chial lavage ﬂuid, can be more informative about
inﬁltrating cells and local chemokines than systemic
measurements of blood. Formalin-ﬁxed, parafﬁn-
embedded diagnostic biopsies of chronic GVHD-
affected tissues can be analyzed in more detail with
multiparameter immunohistochemistry or serve as a
source of securely preserved RNA and microRNA for
multiplex RNA analyses [33,34]. Even if resources to
collect these sample types are not available at all sites,
dedicated large cores/clinical centers should continue
to collect and bank these quality samples locally or
with the intent to ship cryopreserved materials to
centralized repositories, as in the Chronic GVHD Con-
sortium trials.
4. Subject permission to use banked samples in future
research investigations and to exchange materials withother institutions should be incorporated into the
informed consent documents. The use of new tools for
genome sequencing raises ethical concerns relating to
incidental ﬁndings and highlight the need for proper
development of consent documents [35]. Genetic
studies have the potential to identify incidental ﬁndings
of potential health or reproductive importance that are
outside the aims of the study but may have actionable
results [36]. A recent study of exome sequencing sug-
gested such actionable results might be found in 1% of
participants [37]. In the case of transplant recipients,
incidental ﬁndings from testing blood cells could be
relevant to the donor and their close relatives. A model
template for consents for studies involving genomic
sequencing has been developed at the National Cancer
Institutes/Center for Cancer Research clinical research
operations website (https://ccrod.cancer.gov/conﬂu-
ence/display/CCRCRO/Templates) to address these is-
sues for patients and donors.CANDIDATE BIOMARKERS IN CHRONIC GVHD
Potential chronic GVHD biomarkers have been evaluated
in both hypothesis-driven and discovery-based testing for
speciﬁc clinical applications. The data have come primarily
from single centers or from a number of collaborating cen-
ters; in most cases, the ﬁndings have not been assessed as
part of large multicenter trials. Despite promising prior
investigation, few potential biomarkers have been veriﬁed in
independent large cohorts of patients as recommended by
this consensus document [38]. In Table 5, we present pub-
lished candidate chronic GVHD biomarkers, organized by
application (diagnostic, prognostic, risk stratiﬁcation, pre-
dictive), and then in ascending strata based on the strength
of the published evidence. This table illustrates how very few
biomarkers have been identiﬁed from studies incorporating
discovery and independent veriﬁcation. In addition, studies
of chronic GVHD therapeutic response are lacking. Among
potential biomarker applications, we emphasize prognostic,
risk stratiﬁcation, and predictive biomarkers as major pri-
orities for future investigation. As a reminder, biomarkers are
observational correlations and might not necessarily reﬂect
the underlying chronic GVHD pathology. However, they
often do, and the biology of the markers listed in Table 5 will
be discussed elsewhere.
In conclusion, although progress has been made, much
work will be required to verify and qualify the candidate
biomarkers identiﬁed in previous studies, and to implement
high-throughput methods with appropriately collected
specimens for future discovery-based approaches. Close co-
ordination between multi-specialty clinical and laboratory-
based groups, as well as regulatory agencies and industry
partners, will be needed to pursue such studies successfully.
We are conﬁdent that identiﬁcation, veriﬁcation, and quali-
ﬁcation of biomarkers will greatly assist the development
and evaluation of newapproaches for treating chronic GVHD.
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